Sonya Roeloffzen Stokowski
Sonya Roeloffzen joined Pulmocide in 2021 and leads the global regulatory affairs function, working directly with regulators such as the US FDA, EMA, and other national authorities worldwide. She brings more than 23 years of experience in the pharmaceutical industry, having worked in regulatory affairs roles of increasing responsibility in all phases of development, including early- and late-stage product development, multiple registrations and commercializations, life-cycle management, and diligence/partnership of drug, biologic, and combination products, including, Kynmobi®, Zetonna®, Alvesco®, Omnaris®, Xopenex®, Brovana®, Utibron® Neohaler®, Arcapta® Neohaler®, Seebri® Neohaler®, and Vivitrol®. Prior to Pulmocide, Sonya served as Senior Director of Global Regulatory Affairs at Sunovion Pharmaceuticals. Earlier in her career, Sonya held positions at Alkermes, ARIAD Pharmaceuticals, and Pharm-Eco Laboratories. Sonya’s expertise spans the therapeutic areas of pulmonary, Parkinson’s disease, oncology, neuropathic pain, addiction, stroke, depressive disorders, schizophrenia, and bipolar disorder, covering all aspects of regulatory, including clinical, nonclinical, CMC, safety, advertising/promotion, and medical affairs.
Sonya has an M.Sc. degree (chemistry) from St. Francis Xavier University and a B.Sc. degree (honors, chemistry) from Trent University.